• Clinical Technology
  • Adult Immunization
  • Hepatology
  • Pediatric Immunization
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Infectious Disease
  • Obesity Medicine
  • Rheumatology
  • Nephrology
  • Neurology
  • Pulmonology

A Young Cuban Bruiser

News
Slideshow

Walk through this case of unexplained bruising in a young boy that proves signs and symptoms are not always what they appear to be.

The slides above present 2 very interesting cases where presenting signs were not at all what they appeared to be. Dr Jonathan Schneider provides a compact lesson in diagnostics with a flash-back to his early days in medicine. 

Related Content
FDA Expands Indication for Roflumilast Treat Atopic Dermatitis in Children Ages 2 to 5 Image Courtesy of Arcutis

FDA Expands Indication for Roflumilast to Treat Atopic Dermatitis in Children Ages 2 to 5

Grace Halsey
October 6th 2025
Article

The approval of roflumilast 0.05% provides a steroid-free, once-daily treatment option for safe and effective long-term management of pediatric eczema.

2025 AAD Atopic Dermatitis Update: Linda Stein Gold, MD, on New Topical and Biologic Therapies

2025 AAD Atopic Dermatitis Update: Linda Stein Gold, MD, on New Topical and Biologic Therapies

Linda Stein Gold, MD;Sydney Jennings
August 25th 2025
Podcast

Linda Stein Gold, MD, reviews AAD’s 2025 updates on new topical and biologic options for adult atopic dermatitis.

FDA Approves Guselkumab for Pediatric Plaque Psoriasis and Active Psoriatic Arthritis / image credit:©Calin/AdobeStock

FDA Approves Guselkumab for Pediatric Plaque Psoriasis and Active Psoriatic Arthritis

Sydney Jennings
September 30th 2025
Article

The FDA has approved guselkumab for children aged 6 years and older with moderate to severe plaque psoriasis or active psoriatic arthritis, making it the first IL-23 inhibitor authorized for pediatric use.

The Weekly Dose: Pediatric Vaccine Safety, Atopic Dermatitis, Dementia Risk, and Maternal Depression

The Weekly Dose: Pediatric Vaccine Safety, Atopic Dermatitis, Dementia Risk, and Maternal Depression

Sydney Jennings
August 7th 2025
Podcast

Insights on atopic dermatitis treatment preferences, the safety of childhood vaccines, maternal depression’s effect on parenting, and more.

Investigational IL-2 Pathway Agonist Rezpegaldesleukin Shows Promise in Phase 2b RESOLVE-AD Trial / image courtesy of George Washington University School of Medicine

Investigational IL-2 Pathway Agonist Rezpegaldesleukin Shows Promise in Phase 2b REZOLVE-AD Trial

Grace Halsey
September 23rd 2025
Article

The findings highlight rezpegaldesleukin's novel broad-based Treg mechanism, suggesting it may be a potent option with potential for disease modification in atopic dermatitis.

FDA Approves Ruxolitinib for Pediatric Patients Aged 2-11 Years as First Topical JAK Inhibitor for the Age Group / image credit ©Waldenmarus/stock.adobe.com

FDA Approves Ruxolitinib for Pediatric Patients Aged 2-11 Years as First Topical JAK Inhibitor for the Age Group

Grace Halsey
September 19th 2025
Article

Incyte announced the agency's decision, which was based on findings of significant reduction in atopic dermatitis signs and symptoms during the TRuE-AD3 clinical trial.

© 2025 MJH Life Sciences

All rights reserved.